Avelumab mit Valproinsäure bei Virus-assoziiertem Krebs (LATENT)
The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy Eine Studie zur Bewertung der Durchführbarkeit und Wirksamkeit der kombinierten Anwendung von Avelumab mit Valproinsäure zur Behandlung von Virus-assoziiertem Krebs
Up to 20% of all cancers may be associated with a bacterial or viral infection. In some instances, the infection may be one of the reasons why the cancer developed in the first place. One such example is infection with the human papilloma virus (HPV) and the development of cervical or oral cavity cancer.
A viral infection that is chronic may not cause a person symptoms, and may be able to escape detection by a person's own immune system. One of the medications being studied in this clinical trial (Valproic acid) may be able to unmask a chronic viral infection from a person's own immune system, therefore making the virus susceptible to attack by the immune system. In this study Valproic acid is being combined with an immune therapy, Avelumab. Avelumab is an antibody that targets a person's own immune cells, or lymphocytes. Lymphocytes must be activated to fight infections or cancer, but after activation they are deactivated. Avelumab prevents the deactivation of a lymphocyte, in effect "turning off the off-switch." This leads to a re-energizing of a person's immune system, hopefully leading to an attack by the immune system on a person's cancer.
Avelumab is known to be an effective treatment for a variety of cancers, although it has not yet been tested in all cancers. By combining Valproic acid, a treatment which targets the virus that contributed to the development of this type of cancer with Avelumab the investigators hope to enhance the ability of Avelumab to restore the body's own immune defense against the cancer.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
- Plattenepithelkarzinom des Gebärmutterhalses
- Krebs, der mit einer chronischen Virusinfektion verbunden ist
- p16 Positiv SCCHN
- p16 Positives Plattenepithelkarzinom der Vagina oder Vulva
- p16 Positives Plattenepithelkarzinom des Penis
- p16 Positives Plattenepithelkarzinom des Anus oder Analkanals
- EBER Positiver NPC
- EBER Positives Hodgkin- und Non-Hodgkin-Lymphona
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Cross Cancer Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patients must be 18 years of age or older.
-
Patients with the following histologically confirmed diagnoses will be eligible for enrolment: p16 positive SCCHN; squamous cell carcinoma of the cervix; p16 positive squamous cell carcinoma of the vagina or vulva; p16 positive squamous cell carcinoma of the penis; p16 positive squamous cell carcinoma of the anus or anal canal; EBER positive NPC; EBER positive Hodgkins and non-hodgkins lymphoma.
-
Note: patients with p16 positive SCC of unknown primary origin meeting the minimum life expectancy and performance status requirements will also be eligible for enrollment, as the majority of these patients may be assumed to represent HPV-associated disease.
-
Patients must be capable of providing consent to enrolment and treatment.
-
Patients with a performance status of ECOG 0-1(51) will be eligible for enrolment (see appendix 1).
-
Measurable disease must be present according to irRECIST criteria(50).
-
Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening.
-
Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
-
Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
-
Female patients who are breast-feeding should discontinue nursing prior to the first dose of study treatment and until 120 days after the last dose of study drug.
-
Absence of any condition hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial.
-
The following adequate organ function laboratory values must be met:
-
Hematological:
- Absolute neutrophil count (ANC) >1.5 x109/L
- Platelet count >100 x109/L
- Hemoglobin >9 g/dL (may have been transfused)
-
Renal:
o Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
-
Hepatic:
- Total serum bilirubin <1.5x ULN
- AST and ALT <2.5x ULN (or ≤ 5 x ULN for subjects with documented metastatic disease to the liver)
- Serum albumin > 25 g/L
-
Coagulation:
- International Normalized Ratio (INR) <1.5x ULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
- Activated Partial Thromboplastin Time (aPTT) <1.5x ULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
Exclusion Criteria:
- History of pneumonitis requiring treatment with steroids.
- History of interstitial lung disease.
- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- History of another malignancy or a concurrent malignancy;
- Exceptions include patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
- Active brain metastases or leptomeningeal disease.
- Patients with treated brain metastases that are stable for 6 weeks will be eligible for enrolment.
- Diagnosis of immunodeficiency.
- Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Prior organ transplantation including allogenic stem-cell transplantation.
- Known history of human immunodeficiency virus (HIV).
- Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
- Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- Patients with hyperthyroidism or hypothyroidism but that are stable on hormone replacement will not be excluded.
- Active infection requiring systemic therapy.
- Vaccination within 4 weeks of the first dose of Avelumab and while on trials is prohibited except for administration of inactivated vaccines.
- Patient will not be eligible if the patient is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
- Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
- Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
- Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Avelumab with VPA
Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years. |
The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles. 10 mg/kg IV |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Efficacy of Avelumab and VPA
Zeitfenster: 1 year after enrolment of last patient
|
• Assessment of the clinical response rate according to the immune-related RECIST criteria (iRECIST) |
1 year after enrolment of last patient
|
|
Proportion of subjects who complete 4 doses of Avelumab in combination with VPA
Zeitfenster: 1 year after enrolment of last patient
|
• Feasibility analysis, defined as the proportion of subjects who complete 4 doses of Avelumab in combination with VPA over the total duration of the study. |
1 year after enrolment of last patient
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Identifizieren Sie spezifische Virus-assoziierte Krebsarten als Kandidaten für nachfolgende Studien
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
Messung der MHC-Expression
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
Messung zellfreier Tumor-DNA im Blut
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
Phänotypisierung tumorinfiltrierender Lymphozyten
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
Expression von lytischen viralen Genen
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
Zytotoxische T-Lymphozyten-Immunphänotypisierung
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
T-Zell-Rezeptor-Sequenzierung
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
Hsp90-Konzentration im Serum
Zeitfenster: Durch Studienabschluss bis zu 2 Jahre
|
Durch Studienabschluss bis zu 2 Jahre
|
|
|
Overall survival
Zeitfenster: 5 years from final study drug dose
|
defined as the time from the date of enrollment to the date of death, whatever the cause. |
5 years from final study drug dose
|
|
Progression free survival
Zeitfenster: 5 years from final study drug dose
|
Progression free survival is defined as the time between the date of treatment initiation and the date of disease progression or death (whatever the cause), whichever occurs first. |
5 years from final study drug dose
|
|
Number of participants with adverse events
Zeitfenster: Through study completion, up to 2 years
|
• Incidence of adverse events (assessed as the incidence and severity of adverse events, including immune-related adverse events, and the number of discontinuations due to adverse events). |
Through study completion, up to 2 years
|
|
Measurement of Immuno-score
Zeitfenster: Through study completion, up to 2 years
|
AffymetriX Micro-array (Immuno-score) |
Through study completion, up to 2 years
|
|
DNA viral load
Zeitfenster: Through study completion, up to 2 years
|
DNA Quantitative PCR (viral load) |
Through study completion, up to 2 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: John Walker, MD PhD FRCPC, Alberta Health services
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- LATENT
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .